Map Key
Generic Enzyme
Generic kinase
Protein kinase
Lipid kinase
Generic phosphatase
Protein phosphatase
Lipid phosphatase
Generic phospholipase
Generic protease
Metalloprotease
G-alpha
RAS - superfamily
G beta/gamma
Regulators (GDI, GAP, GEF)
Generic channel
Ligand-gated channel
Voltage-gated channel
Transporter
Normal process
Pathological process
Positive effect
Negative effect
Unspecified effect
Technical link
Disrupts in disease
Emerges in disease
Enhances in disease
Weakens in disease
Organsim specific interaction

Generic binding protein
Receptor ligand
Cell membrane glycoprotein
Transcription factor
DNA
RNA
Compound
Inorganic ion
Predicted metabolite or user's structure
Reaction
Generic receptor
GPCR
Receptors with enzyme activity
Mitochondria
EPR
Golgi
Nucleus
Lysosome
Peroxisome
Cytoplasm
Extracellular

Normal process
Pathological process
Binding
Cleavage
Covalent modifications
Phosphorylation
Dephosphorylation
Transformation
Transport
Catalysis
Transcription regulation
MicroRNA binding
Competition
Influence on expression
Unspecified interactions
Pharmacological effect
Toxic effect
Group relation
Complex subunit
Similarity reaction
A complex or a group
Organism specific object

Immune response Oncostatin M signaling via MAPK in human cells


Log In to Post A Comment

Immune response Oncostatin M signaling via MAPK in human cells

Oncostatin M signaling via MAPK in human cells

Oncostatin M is a multifunctional cytokine produced by activated T lymphocytes,monocytes and microglia. It is structurally and functionally related to the subfamily ofhematopoietic and neurotrophic cytokines known as the Interleukin 6 (IL6)-type cytokinefamily [1].

Human Oncostatin M and mouse Oncostatin M signaling pathways aredifferent. Human Oncostatin M signaling is mediated by its binding to two receptorcomplexes: the type I OSM receptor complex ( LIF receptor ) consisting ofInterleukin 6 signal transducer ( gp130 ) and Leukemia inhibitory factor receptorsubunits ( LIFR ), and the type II OSM receptor complex ( OSM receptor )consisting of gp130 and OSM receptor beta ( OSMR ) subunits. MouseOncostatin M uses only one receptor complex: OSM receptor, but not LIFreceptor [2].

Binding of Oncostatin M to its receptor subunits ( gp130 and OSMR(or LIFR )) induces MAPK signaling pathway via several routes, specificallyProtein tyrosine phosphatase, non-receptor type 11 ( SHP-2 )-dependent and Srchomology 2 domain containing transforming protein 1 ( Shc )-dependent Growthfactor receptor-bound protein 2 ( GRB2 ) activation.

SHP-2 is recruited to LIFR and gp130 subunits of LIFreceptor or OSM receptor [3], [4], [2].Then, SHP-2 is activated by phosphorylation, for instance, by Janus kinase 1 (JAK1 ) [5], [2]. Phosphorylated SHP-2 acts as adocking target for the adaptor protein GRB2, which provides a link to thev-Ha-ras Harvey rat sarcoma viral oncogene homolog ( H-Ras ) pathway ofMitogen-activated protein kinases 1-3 ( ERK1/2) activation [2]

Shc, in turn, is activated via OSMR subunit of OSM receptor.OSMR recruits Shc as a downstream signaling molecule and initiates MAPKcascade via GRB2 [6].

Activated GRB2 is bound with the GTP-exchange factor Son of sevenless homolog (SOS ). SOS interacts with H-Ras, and H-Ras recruits v-raf-1murine leukemia viral oncogene homolog 1 ( c-Raf-1 ). Activated c-Raf-1then transmits its signal via the Mitogen-activated protein kinase kinases ( MEKs)/ ERK1/2 cascade, leading to gene expression [2].

ERK1/2, in turn, activated by phosphorylation some transfactors.

Oncostatin M -induced ERK1/2 may activate transcription factor Earlygrowth response 1 ( EGR1 ), which, along with CCAAT/enhancer binding protein beta( C/EBPbeta ), stimulates transcription of lipid metabolism regulator - Lowdensity lipoprotein receptor ( LDLR ) [7], [8], [9]. High EGR1 transcription in this case may be explained byautotranscription [10].

Oncostatin M -induced ERK1/2 may participate in regulation of remodelingof the extracellular matrix. ERK1/2 activates transcription of TIMPmetallopeptidase inhibitor 1 ( TIMP-1 ) and Matrix metallopeptidase 1 (MMP-1 ). Activation of the ERK1/2 and Signal transducer and activator oftranscription 1 ( STAT1 ), which leads to v-fos FBJ murine osteosarcoma viraloncogene homolog ( c-Fos ) expression and activation, is involved in transcriptionof TIMP-1 and MMP-1 [11].

Oncostatin M/ ERK1/2 pathway participates in regulation of inflammatoryprocesses. For example, Oncostatin M induces Chemokine ligand 2 ( CCL2)expression in osteoblasts. Activation of the ERK1/2 and STAT1 pathways,which leads to c-Fos expression and activation, is also involved in the process[12].

In addition, Oncostatin M/ ERK1/2 pathway leads to down-regulation ofPeroxisome proliferator-activated receptor gamma ( PPAR-gamma ) (e.g., viaactivation of STAT1 [13]), thus inhibiting the adipogenesis [14].

Oncostatin M can also induce activation of Mitogen-activated protein kinases8-10 ( JNK(MAPK8-10) ) and Mitogen-activated protein kinases 11 - 14 (p38MAPK ) [15], [16], [17]. Signaltransduction pathways resulting in their activation, however, are poorly understood.Probably, Oncostatin M activates JNK(MAPK8-10) and p38MAPK viaGRB2/ SOS/ Ras-related C3 botulinum toxin substrate 1 ( Rac-1 )(or H-Ras )/ mitogen-activated protein kinase kinase kinase (e.g., MEKK1 )/ mitogen-activated protein kinase kinases (e.g., MEK3(MAP2K3) orMEK4(MAP2K4) ) [18], [15], [16].

Oncostatin M -induced p38MAPK and JNK(MAPK8-10) participate inregulation of remodeling of the extracellular matrix. For example, p38MAPK takespart in activation transcription of TIMP-1 via AP-1 transfactors (e.g.,c-Fos and others) production in both cell types [19], [20]. Oncostatin M -induced JNK(MAPK8-10) may activate transcriptionof MMP-1, Matrix metallopeptidase 3 ( Stromelysin-1 ), and Matrixmetallopeptidase 13 ( MMP-13 ), possible, using transfactors STAT1and/or  Jun oncogene ( c-Jun ) [18], [15].